Nachman brings more than 25 years of experience to the transcatheter aortic valve replacement (TAVR) system maker’s board. He previously held senior operating roles at Johnson & Johnson. That included serving as company group chair of cardiovascular and specialty solutions and vision groups within J&J Medical Devices.
He was a member of the company’s medical devices group operating committee as well. At J&J, Nachman led a portfolio of six different medical device businesses. Before that, he had various roles, including worldwide president of Biosense Webster and Cordis.
“We are thrilled to welcome Shlomi to the JenaValve board of directors,” said John Kilcoyne, JenaValve CEO. “His experience as both an executive and board member across innovative cardiovascular device businesses further strengthens the operating expertise of our board. His track record of driving commercial growth and technological development at J&J is a testament to the strength of his leadership.”
Nachman called the present “an exciting time” in JenaValve’s development.
I hope to lend my experience to help JenaValve achieve its mission of delivering life-changing outcomes to patients suffering from AR and AS,” he said. “JenaValve is well-positioned to become a major contributor to the structural heart space. I look forward to working with this world-class board and management team.”